CECAD Microsite

Christian Reinhardt Lab

We congratulate Dr. Anna Schmitt on a very successful PhD Defense!


On December 19th, Dr. Anna Schmitt defended her PhD with the title "Targeting a defective DNA damage response in KRAS-mutant adenocarcinomas".

Dr. Schmitt and colleagues evaluated in two different Kras-mutant mouse models how ATM deficiency affects tumor progression and response to therapy. Two targeted therapy approaches could be established in ATM-deficient tumors, namely the PARP inhibitor olaparib as well as the ATR inhibitor VE-822. Taken together, Dr. Schmitt’s results provide a functional rationale to profile human tumors for disabling ATM mutations and for the use of PARP and ATR inhibitors to potentially improve treatment in ATM-mutant NSCLC and PDAC.